头孢哌酮/他唑巴坦体外抗菌活性研究

Study on in vitro Antibacterial Activity of Cefperazone/Tazobactam

目的：研究头孢哌酮／他唑巴坦（Ｃｅｆｐｅｒａｚｏｎｅ／ｔａｚｏｂａｃｔａｍ ＣＦＰ／ＴＡＺ ４：１）体外抗菌活性。方法：临床分离致病菌６０１株，经Ｖｉｔｅｋ或ＡＰＩ系统鉴定到种，用Ｎｉｔｒｏｃｅｐｈｉｎ纸片法测试各菌β－内酰胺酶及Ｖｉｔｅｋ—５０６卡测定超广谱β－内醚胺酶（ＥＳＢＬ）。采用琼脂中板二倍稀释法测定最低抑菌浓度（ＭＩＣ）；试管二倍稀释法测定最低杀菌浓度（ＭＢＣ）并绘制杀菌曲线；测试细菌接种量，培养基ｐＨ和血清蛋白含量对ＭＩＣ的影响。结果：头孢哌酮／他唑巴坦４：１配比对产 ＥＳＢＬ菌株的 ＭＩＣ５０和 ＭＩＣ９０分别比单头孢哌酮低 ３２－６４倍及 １６－３２倍，低于头孢哌酮／舒巴坦（ＣＦＰ／ＳＢＴ）和哌拉西林／他唑巴坦（ＰＩＰ／ＴＡＺ）２倍和４倍，本品杀菌活性强于单头孢哌酮，但与头孢哌酮／舒巴坦１：１和哌拉西林／他唑巴坦８：１基本一致，细菌接种量、培养基ｐＨ和血清蛋白含量对本品抗菌活性影响小。结论：ＣＦＰ／ＴＡＺ ４：１是一个有效的β－内酰胺酶的复合制剂，有进一步研究开发价值。

OBJECTIVE: The antibacterial activity in vitro of cefperazone/tazobactam was evaluated. METHODS: Cefperazone/tazobactam (4:1) against 601 clinical isolated strains was compared with cefperazone, tazobactam, cefperazone/sulbactam, piperacillinltazobactam and impipenenilceilastatin. Minimal inhibitory concentrations (MIC) were measured by agar dilution method and minimal bactericidal concentrations (MBC) were measured by broth dilution method. RESULTS: The antibacterial activity of cefperazone/tazobactam (4:1), the MIC50 and MIC90 against the strains producing extended spectrum b-lactamases (ESBLs) were 32-64 times and 16-32 times lower than cefperazone and were 2 times and 4 times lower than cefperazone/sulbactam and piperacillin/tazobactam. The bactericidal activity of cefperazone/tazobactam is better than cefperazone and similar as cefperazone/ sulbactam (1:1) and piperacillin/tazobactam (8:1). The inoculum size, pH and concentration of serum protein did not influence the in vitro the activity of cefperazone/tazobatam (4:1). CONCLUSION: Cefperazone/tazobactam (4:1) is an effective antibiotic containing β-lactamases inhibitor and valuable to be investigated.